Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes : A randomized controlled trial

Takase, Takahiro; Nakamura, Akinobu; Yamamoto, Chiho; Nomoto, Hiroshi; Miya, Aika; Dannoura, Midori; Cho, Kyu Yong; Kurihara, Yoshio; Manda, Naoki; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes : A randomized controlled trial

Takase, Takahiro; Nakamura, Akinobu; Yamamoto, Chiho et al.

Journal of Diabetes Investigation, 2019, 10, 699-705

Permalink : https://hdl.handle.net/2115/74767

このアイテムのアクセス数:823件（2026-08-15 14:08 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Takase_et_al-2019-Journal_of_Diabetes_Investigation	pdf	311 KB	574

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/74767
タイトル	Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes : A randomized controlled trial
著者	Takase, Takahiro ; Nakamura, Akinobu ; Yamamoto, Chiho ; Nomoto, Hiroshi ; Miya, Aika ; Dannoura, Midori ; Cho, Kyu Yong ; Kurihara, Yoshio ; Manda, Naoki ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Takase, Takahiro
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Yamamoto, Chiho
著者名 Nomoto, Hiroshi
著者名 Miya, Aika
著者名 Dannoura, Midori
著者名 Cho, Kyu Yong
著者名 Kurihara, Yoshio
著者名 Manda, Naoki
著者名 Aoki, Shin
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
キーワード	Dulaglutide
	Treatment satisfaction
	Type 2 diabetes
発行日	2019-05
出版者	Wiley
収録物名	Journal of Diabetes Investigation
巻(号)	10
ページ	699-705
抄録	Aims/Introduction: We compared treatment satisfaction in type 2 diabetes patients taking daily and weekly glucagon-like peptide-1 receptor agonists. Materials and Methods: The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial. The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months. Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group). The primary outcome was the change in the Diabetes Treatment Satisfaction Questionnaire score from baseline to week 12 in the two groups. The secondary outcomes comprised changes in the Diabetes Therapy-Related Quality of Life score, body mass and glycemic control. Results: A total of 33 participants were initially enrolled in the trial, and 31 participants completed the protocol. The change in the Diabetes Treatment Satisfaction Questionnaire score in the Dula group was significantly greater than that in the Lira group (+0.1 – 4.7 in the Lira group vs +4.9 – 5.2 in the Dula group; P = 0.013). The change in Diabetes Therapy- Related Quality of Life score in the Dula group was significantly greater than that in the Lira group (-3.7 – 6.9 vs +8.9 – 15.1; P = 0.007). There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin. Conclusions: Weekly administration of dulaglutide was superior to liraglutide with regard to treatment satisfaction in patients with type 2 diabetes, in the absence of any negative effect on glycemic control.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2040-1116
関連情報	PMID 30076787
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.12906